Start-up Successes

A total of 30 research projects with spin-off potential have been awarded in six  calls.

14 successful spin-offs have been realized so far.


Founded as a spin-off of the Technical University of Munich in October 2022, INVITRIS uses bacteriophages for the therapy of antibiotic-resistant infections and has developed a special technology to produce for the first time genetically optimized bacteriophages in vitro for the therapy of antibiotic-resistant infections.


Fusix Biotech's platform technology is based on a hybrid virus construct with a unique fusion-based mechanism of action that improves safety and efficacy in clinical use and enables systemic administration. The start-up was founded in spring 2022 out of the Technical University of Munich.


OpSYon Therapeutics was founded in early 2022 as a spin-off from the LMU Munich Gene Center. The aim is to develop novel cancer immunotherapies that combine immune checkpoint inhibition with antibody-based tumor targeting in one drug.


Plectonic Biotech develops nanoswitches for antibodies to improve the specificity and effectiveness of immunotherapies for cancer. As a spin-off of the Technical University of Munich, it was founded in January 2022.


Smartbax is a spin-off of the Technical University of Munich and was founded in April 2021. Smartbax develops novel antibacterial compounds against multidrug-resistant bacteria and difficult-to-treat biofilms.


Roscue Therapeutics was founded at the end of 2020. The spin-off from the Helmholz Zentrum München aims to develop and commercialize ferroptose modulators for therapeutic use.


Also founded in early 2020, ImmuCon from the University of Regensburg has developed an antibody for combination therapy with steroids for the treatment of acute exacerbations of multiple sclerosis.


Knowing01 is a spin-off of the Institute of Computational Biology at Helmholtz Munich, founded in early 2020 and has developed a big data analyzing software to identify biomarkers and drug targets for personalized therapies. 


Tubulis was founded in July 2019. Tubulis generates uniquely matched protein-drug conjugates, unlimited by indication, by combining proprietary novel technologies with disease-specific biology. The goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients.


As a spin-off from the University Hospital of Würzburg, Cherry biolabs was founded in the beginning of 2019. The company has developed a new antibody format that is supposed to lead T-cells even more precisely to cancer cells. The idea is based on two incomplete antibody fragments (hemibodies), each directed against a different target structure on the cancer cells, which only become a functional unit in the tumour tissue.


T-CURX was founded in spring 2017. The spin-off of the University Hospital of Würzburg is working on a new generation of CAR T-cells that have a stronger antitumor effect and at the same time prevent an excessive reaction of the immune system.


Preomics
is a spin-off of the Max Planck Institute of Biochemistry in Martinsried. The company was founded in early 2016, to bring mass spectrometry-based proteomics into clinical application. 


2014, MetaHeps was founded, a spin-off of the LMU Munich. The company has developed an innovative platform technology for the prediction of drug-induced liver injury in individual patients.


Trianta Immunotherapies, which focuses on personalized immunotherapies, is a spin-off of the Helmholtz Center Munich. The start-up was taken over by Medigene located in Martinsried shortly after its foundation. Focussing on Trianta’s innovative immunotherapies, Medigene AG has more than quadrupled its market capitalisation.